Clinical Orthopaedics and Related Research ®

A Publication of The Association of Bone and Joint Surgeons ®

Tumor 247 articles


Revision Distal Femoral Arthroplasty With the Compress® Prosthesis Has a Low Rate of Mechanical Failure at 10 Years

Melissa N. Zimel MD, German L. Farfalli MD, Alexandra M. Zindman BA, Elyn R. Riedel MA, Carol D. Morris MD, Patrick J. Boland MD, John H. Healey MD

Patients with failed distal femoral megaprostheses often have bone loss that limits reconstructive options and contributes to the high failure rate of revision surgery. The CompressCompliant Pre-stress (CPS) implant can reconstruct the femur even when there is little remaining bone. It differs from traditional stemmed prostheses because it requires only 4 to 8 cm of residual bone for fixation. Given the poor long-term results of stemmed revision constructs, we sought to determine the failure rate and functional outcomes of the CPS implant in revision surgery.

Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?

Zhengfu Fan MD, PhD, Shreyaskumar Patel MD, Valerae O. Lewis MD, B. Ashleigh Guadagnolo MD, Patrick P. Lin MD

Extraosseous osteosarcoma is rare, and the most appropriate therapy is unclear because there are few studies regarding its treatment. The effectiveness of radiation and chemotherapy remains uncertain owing to conflicting results in previous reports.

A 26-year-old Woman With Bilateral Leg Pain and Pruritus

S. M. Morell MD, Jerad M. Gardner MD, L. J. Suva PhD, C. O. Montgomery MD

CT-based Structural Rigidity Analysis Is More Accurate Than Mirels Scoring for Fracture Prediction in Metastatic Femoral Lesions

Timothy A. Damron MD, Ara Nazarian PhD, Vahid Entezari MD, Carlos Brown MD, William Grant EdD, Nathan Calderon MSc, David Zurakowski PhD, Richard M. Terek MD, Megan E. Anderson MD, Edward Y. Cheng MD, Albert J. Aboulafia MD, Mark C. Gebhardt MD, Brian D. Snyder MD, PhD

Controversy continues regarding the appropriate assessment of fracture risk in long bone lesions affected by disseminated malignancy.

Does Microwave Ablation of the Tumor Edge Allow for Joint-sparing Surgery in Patients With Osteosarcoma of the Proximal Tibia?

Jing Li MD, PhD, Zheng Guo MD, PhD, Zhen Wang MD, Hongbin Fan MD, Jun Fu MD

Joint-sparing surgery of a patient’s native joint for osteosarcoma likely affords better function and comparable survival. However, it sometimes is challenging to resect a juxtaarticular osteosarcoma in a way that preserves the affected epiphysis because wide margins are necessary to minimize the risk of local recurrence. If there was a method to resect a tumor close to the joint and treat a potentially positive margin to prevent recurrence, it might allow salvage of a joint that otherwise might be lost.

2015 Marshall Urist Young Investigator Award: Prognostication in Patients With Long Bone Metastases: Does a Boosting Algorithm Improve Survival Estimates?

Stein J. Janssen MD, Andrea S. Heijden BSc, Maarten Dijke BSc, John E. Ready MD, Kevin A. Raskin MD, Marco L. Ferrone MD, Francis J. Hornicek MD, MS, PhD, Joseph H. Schwab MD, MS

Survival estimation guides surgical decision-making in metastatic bone disease. Traditionally, classic scoring systems, such as the Bauer score, provide survival estimates based on a summary score of prognostic factors. Identification of new factors might improve the accuracy of these models. Additionally, the use of different algorithms—nomograms or boosting algorithms—could further improve accuracy of prognostication relative to classic scoring systems. A nomogram is an extension of a classic scoring system and generates a more-individualized survival probability based on a patient’s set of characteristics using a figure. Boosting is a method that automatically trains to classify outcomes by applying classifiers (variables) in a sequential way and subsequently combines them. A boosting algorithm provides survival probabilities based on every possible combination of variables.

Creating an Intraoperative MRI Suite for the Musculoskeletal Tumor Center

Nathan W. Mesko MD, David M. Joyce MD, Hakan Ilaslan MD, Michael J. Joyce MD

Altered anatomy in a previously irradiated surgical bed can make accurate localization of anatomic landmarks and local recurrence nearly impossible. The use of intraoperative MRI (iMRI) has been described in neurosurgical settings, but to our knowledge, no such description has been made regarding its utility for local recurrence localization in sarcoma surgery.

Does CT-based Rigidity Analysis Influence Clinical Decision-making in Simulations of Metastatic Bone Disease?

Ara Nazarian PhD, Vahid Entezari MD, Juan C. Villa-Camacho MD, David Zurakowski PhD, Jeffrey N. Katz MD, Mary Hochman MD, Elizabeth H. Baldini MD, Vartan Vartanians MD, Max P. Rosen MD, Mark C. Gebhardt MD, Richard M. Terek MD, Timothy A. Damron MD, Michael J. Yaszemski MD, PhD, Brian D. Snyder MD, PhD

There is a need to improve the prediction of fracture risk for patients with metastatic bone disease. CT-based rigidity analysis (CTRA) is a sensitive and specific method, yet its influence on clinical decision-making has never been quantified.

Is MR-guided High-intensity Focused Ultrasound a Feasible Treatment Modality for Desmoid Tumors?

Raffi S. Avedian MD, Rachelle Bitton PhD, Garry Gold MD, Kim Butts-Pauly PhD, Pejman Ghanouni MD, PhD

MR-guided high-intensity focused ultrasound is a noninvasive treatment modality that uses focused ultrasound waves to thermally ablate tumors within the human body while minimizing side effects to surrounding healthy tissues. This technology is FDA-approved for certain tumors and has potential to be a noninvasive treatment option for extremity soft tissue tumors. Development of treatment modalities that achieve tumor control, decrease morbidity, or both might be of great benefit for patients. We wanted to assess the potential use of this technology in the treatment of extremity desmoid tumors.

Do Mesenchymal Stromal Cells Influence Microscopic Residual or Metastatic Osteosarcoma in a Murine Model?

Megan E. Aanstoos MS, Daniel P. Regan DVM, Ruth J. Rose DVM, Laura S. Chubb BS, Nicole P. Ehrhart VMD

Mesenchymal stromal cells (MSCs) have been shown in rodent models to promote primary and pulmonary metastatic sarcoma growth when injected in the presence of gross tumor. In theory, this would limit their use in a clinical setting after limb salvage treatment for osteosarcoma. Although concerning, these models do not translate to the clinical setting wherein MSCs could be used after primary tumor resection to aid in bone healing and incorporation of tumor endoprostheses. If we can determine whether the use of MSCs in this setting is safe, it might improve our ability to augment bone healing in patients undergoing limb salvage.